Brand-name, generics firms fight over bulk drug supplies

11/11/2009 | Wall Street Journal, The

Complaints from generic-drug firms prompted the Federal Trade Commission to look into practices of brand-name companies that refuse to supply bulk quantities of medicines that can aid the development of copycat drugs. The FTC did not say whether it is investigating. Meanwhile, Dr. Reddy's Laboratories filed a petition with the FDA to clarify whether brand-name manufacturers can hide behind a drug-safety program that restricts the distribution of certain treatments to prevent misuse.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT